Added to YB: 2026-07-28
Pitch date: 2026-07-24
IMMX [bullish]
Immix Biopharma, Inc.
+0.7%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
Market Cap
$606.5M
Pitch Price
$8.63
Price Target
21.20 (+149%)
Dividend
N/A
EV/EBITDA
-14.57
P/E
-9.59
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Outpatient Disruptor or Micro-Cap Gamble? : The Asymmetric Case for Immix Biopharma ($IMMX)
IMMX: BULLISH, PT $21.20 vs $8.95 (+137%). NXC-201 BCMA CAR-T for r/r AL amyloidosis w/ 1-day median CRS, 0 ICANS enables outpatient community delivery. 95% CR, MRD-negative. $3B market, no approved cell therapies. $150M raise funds into 2028. Catalysts: Sept'26 NEXICART-2 readout, Dec'26 rolling BLA, 2027 launch/partnership. Peak sales $850M. Risks: single-arm trial, cardiac CRS deaths, durability, thin mgmt, big pharma cannibalization; downside $2-3.
Read full article (5 min)